X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients

Oliver Sartor joins Charles Ryan in a discussion on a Phase 4 registry trial in men with metastatic castration-resistant prostate cancer (mCRPC).  The IMPACT study analyses suggested that overall survival (OS) was longer in treated and control patients with low baseline PSA, and OS benefit was greatest for sipuleucel-T versus control in the patients with the lowest PSA (Schellhammer Urol 2013).

Watch the full interview here.

source: Oliver Sartor - Uro Today